Splash

Media

View our latest materials to follow our progress in tackling respiratory diseases.
Splash
Media

Filters

Email Alerts

Subscribe to our email alerts

September 2 2021Regulatory
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021

Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,

August 31 2021Regulatory
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference

LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company

August 5 2021Regulatory
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update

ENHANCE Phase 3 program on track to report top-line data in 2022 Up to $219 million strategic collaboration with Nuance Pharma in Greater China Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA)

July 27 2021Regulatory
Verona Pharma Announces August 2021 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the

July 22 2021Financial News, Regulatory
Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on

June 10 2021Company News, Financial News, Regulatory
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company). Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties. Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China.

Email Alerts

Subscribe to our email alerts

Splash

© Verona Pharma plc 2021. All rights reserved